Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance?

PURPOSE OF REVIEW: Cabotegravir is a potent integrase strand transfer inhibitor (INSTI) recently approved as a long-acting injectable formulation for HIV prevention (CAB-LA). We summarize what is known about cabotegravir pharmacokinetics, activity, and emergence of resistance from in vitro, macaque...

Descripción completa

Detalles Bibliográficos
Autores principales: Parikh, Urvi M., Koss, Catherine A., Mellors, John W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
The Science of Prevention (R Heffron and K Ngure, Section Editors)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508028/
https://www.ncbi.nlm.nih.gov/pubmed/36112336
http://dx.doi.org/10.1007/s11904-022-00616-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508028/
https://www.ncbi.nlm.nih.gov/pubmed/36112336
http://dx.doi.org/10.1007/s11904-022-00616-y

Ejemplares similares